KLOW (KL80)
Longevity peptide researched for aging pathways.
KLOW (KL80)
Background
KLOW (also designated KL80) is a research blend that commonly combines the melanocortin-derived tripeptide KPV with GHK-Cu, BPC-157, and TB-500. It is studied on the rationale of pairing anti-inflammatory melanocortin signaling (KPV) with matrix-remodeling and repair-associated peptides.
As with other blends, no controlled studies address this specific composition; supporting evidence is drawn from separate preclinical studies of each constituent. See the individual component entries.
Selected literature
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences. 2018;19(7):1987.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide BPC 157 and musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
KLOW (KL80) is a research blend; its component compounds (KPV, GHK-Cu, BPC-157, TB-500) are investigational or non-trademark-restricted and carry the attributions noted on their individual entries. Catalyst Research Labs is not affiliated with any branded product. Supplied as reference material only.